NIIMBL Injects $9.7M to Fortify US Biopharma Leadership

NEWARK, Del. – May 19, 2026 – The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) today announced a significant $9.7 million investment aimed at tackling some of the most pressing challenges in medicine manufacturing and workforce development. The funding, part of the institute's Project Call 9.1, will be distributed across eight new projects, uniting 39 organizations from industry, academia, and government to advance the nation's biopharmaceutical capabilities.

This latest initiative brings NIIMBL's total portfolio to 230 projects, with a cumulative investment of over $216 million since its inception in 2017. The new projects are sharply focused on two critical fronts: pioneering new technologies to make drug production faster and more reliable, and building a skilled, diverse talent pool to sustain a rapidly evolving industry.

Revolutionizing Production with AI and Advanced Analytics

Five of the new projects are dedicated to technological breakthroughs, with a heavy emphasis on artificial intelligence, real-time data analytics, and the complex manufacturing of next-generation treatments like gene therapies. These efforts aim to solve critical bottlenecks that can slow the delivery of life-saving medicines to patients.

Several projects target the production of adeno-associated viruses (AAV), the primary delivery vehicle for many gene therapies. While revolutionary, manufacturing AAVs at scale and with consistent quality remains a major industrial hurdle. A project led by Michigan Technological University, in partnership with industry giants like Janssen and Cytiva, will develop methods for continuous and automated purification of AAVs. This builds on the university's existing expertise in detecting impurities, aiming to streamline a process that is currently a significant bottleneck.

Similarly, a Massachusetts Institute of Technology (MIT)-led team will focus on the 'upstream' part of the process, working to increase the yield of high-quality AAVs in bioreactors. Another project, spearheaded by North Carolina State University, will apply Bayesian optimization—a sophisticated form of AI—to intelligently refine AAV purification.

"These new technology projects represent the kind of innovation needed to strengthen the nation's biopharmaceutical manufacturing capabilities," said Sandeep Kedia, NIIMBL Senior Technology Fellow and Project Call Program Lead. "By bringing together advanced process analytical technologies, AI-driven optimization, and next-generation production platforms, our members are helping accelerate the adoption of transformative technologies across the industry."

Other technological initiatives include the University of Delaware's project with Sanofi and Waters Technologies Corporation to develop 'digital twins'—virtual models of manufacturing processes that use AI to predict outcomes and optimize production in real-time. Another effort, led by the University of Houston, seeks to create a continuous fiber-optic probe for the real-time detection of antibodies, a foundational technology for improving quality control across a wide range of biologic drugs.

Building the Biopharma Workforce of Tomorrow

Recognizing that technology alone is not enough, NIIMBL has also directed significant resources toward three ambitious workforce development projects. These initiatives are designed to address a critical talent shortage that industry leaders have identified as a major risk to growth and innovation.

One of the most forward-thinking projects, led by the National Center for Therapeutics Manufacturing at Texas A&M University, is focused on "Creating a Neurodiverse Talent Pipeline for the Biomanufacturing Industry 2.0." In collaboration with Pfizer, Janssen, and others, this project aims to develop pathways for neurodivergent individuals to enter and thrive in the biomanufacturing workforce, tapping into a pool of talent whose unique skills are often overlooked.

Another project, led by Philadelphia's University City Science Center with partners CSL Behring and GlaxoSmithKline, will give potential candidates firsthand experience with careers in the field. Meanwhile, The Wistar Institute is launching the BioPharma Apprenticeship & Training Hub (BioPATH), a program designed to provide practical, hands-on training that directly maps to industry needs.

"Our workforce initiatives are designed to meet talent needs head‑on by creating more innovative pathways into biomanufacturing careers," said John Balchunas, NIIMBL Workforce Director. "These new projects will strengthen partnerships and ensure that learners can gain the skills needed to thrive in a rapidly evolving biopharma industry."

A Strategic Investment in National Competitiveness

Beyond the specific technologies and training programs, this $9.7 million investment represents a strategic move to bolster U.S. economic and national security. NIIMBL is a key part of Manufacturing USA, a network of federally sponsored institutes funded through the National Institute of Standards and Technology (NIST) to enhance domestic industrial competitiveness.

Recent global events have exposed the fragility of international supply chains, particularly for critical medicines. In response, there has been a strong bipartisan push to increase domestic biopharmaceutical manufacturing capacity, ensuring the U.S. is not overly reliant on foreign nations for essential drugs. NIIMBL's mission directly supports this goal by fostering the ecosystem needed for a robust domestic industry.

By funding projects that bring together academic pioneers from institutions like MIT and industry leaders such as Amgen, Genentech, and Bristol-Myers Squibb, NIIMBL acts as a crucial bridge between foundational research and commercial application. This public-private partnership model allows for the sharing of risks and accelerates the adoption of new standards and technologies across the entire sector.

The dual focus on both cutting-edge automation and human capital is critical. The projects developing AI-driven digital twins and automated purification systems are creating the factories of the future, while the workforce initiatives are simultaneously training the people needed to run them. This integrated strategy is fundamental to securing America's long-term leadership in a global bioeconomy that is only growing in importance.